All In Biotech

Drug Trial Radar · NCT06726096

Phase III Trial of VDJ001 In Patients With Moderate-to-severe Active Rheumatoid Arthritis

Randomized,Double-blind,Placebo,Positive-controlled Phase III Trial of VDJ001 In Patients With Moderate-to-severe Active Rheumatoid Arthritis

Last checked: Nov 20, 2026Latest source record: Aug 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingPhase 3. Randomized with 615 participants. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

615

Planned (sponsor's estimate)

Start

Apr 9, 2025

Primary completion

Apr 20, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Beijing VDJBio Co., LTD.Industry
Sponsor type
Industry
First posted
Dec 10, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A multicenter, randomized, double-blind, placebo-controlled, and active drug-controlled Phase III pivotal clinical trial of recombinant humanized anti-interleukin-6 receptor monoclonal antibody injection (VDJ001) for the treatment of moderate-to-severe active rheumatoid arthritis with poor response to methotrexate

Conditions

  • Rheumatoid Arthritis (RA)
  • Anti IL-6R

Interventions

  • Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody InjectionBiological

    The drug was administered once every 4 weeks. Other Names: Tocilizumab Injection placebo control

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects achieving ACR50 at week 24 (W24).Time frame: 24 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.